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Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID-19 
As of May 19, 2020, there are in total 4,986,200 laboratory-confirmed Coronavirus 
disease-2019 (COVID-19) cases. 2% (45,425) out of 2,657,390 active COVID-19 cases 
are critically ill and might be requiring intensive care support.(1,2) Unfortunately, even 
after six months since its first detection, we still do not have any definitive treatment 
options for COVID-19 pneumonia. Recently, the use of human convalescent plasma is 
being considered as a potential option for the treatment of COVID-19.(3) 
Convalescent Plasma Therapy During Previous Outbreaks: Lessons from The Past 
Experience 
The basic concept for use of convalescent plasma in COVID-19 is as a delivery system 
for viral neutralizing antibodies, that is to confer passive immunity. Given the fact that 
we do not have reliable targeted drugs or a vaccine yet, the option of convalescent plasma 
seems reasonable to boost the immune system of infected patients or susceptible 
population immediately. This is not a new concept, rather this has been utilized for over 
100 years, even predating the discovery of antibiotics. With regards to the previous 
outbreaks, experience with convalescent plasma have shown mixed results(4–6). Soo et 
al reported a low mortality rate (p =0.049) and shorter hospital stay (p= 0.001) in patients 
with SARS by using convalescent plasma(4). Contrarily, the use of convalescent plasma 
therapy has been found to be of uncertain benefit in the 2013 African Ebola epidemic(6). 












Many studies have confirmed that not all Ebola survivors have anti-Ebola antibodies and 
hence plasma extraction from such donors might not be beneficial for the treatment of 
Ebola disease(7). 
Convalescent Plasma Therapy During COVID-19 Pandemic 
Preliminary results on using convalescent plasma in COVID-19 patients have shown 
positive results(8,9).Shen et al used convalescent plasma [(IgG) binding titer greater than 
1:1000] therapy in five mechanically ventilated patients. There were significant 
laboratory and clinical improvement in all patients, with three patients even discharged at 
the time of reporting. (8) Similarly, Daun et al in their 10-patient study with convalescent 
plasma (neutralizing antibody titers above 1:640) found an increase of oxyhemoglobin 
saturation, increased lymphocyte counts, and decreased CRP levels. Serum SARS-CoV-2 
RNA load was also checked in all patients that confirmed a 100% clearance of viremia, 
although data were not presented on respiratory tract clearance.(9) Rajendran et al 
reviewed five studies recently reported on the use of convalescent plasma in COVID-19 
patients(10,11) The major findings of this review were [1] reduced mortality in critically 
ill patients [2] disappearance of SARS-CoV-2 RNA was observed in the majority of 
patients [3] improvement in clinical symptoms and radiological shadows of the patients 
after convalescent plasma therapy [4] No significant adverse effects secondary to plasma 
therapy were noted.  
Although the convalescent plasma therapy concept is old, the COVID-19 disease is just 
six months old. Hence, a large degree of uncertainty exists as to donor selection, patient 
eligibility, indications, and side effects that merit further discussion(11). 












Donor Selection and Timing of Plasma Extraction: The U.S. Food and Drug 
Administration (FDA) has recommended the following guidance for timing of COVID-
19 convalescent plasma collection:  
 Scenario A (Clinical findings based): Donors’ symptoms should have completely 
resolved at least 28 days prior to donation. 
 Scenario B (Clinical plus laboratory investigation based): Donors’ symptoms 
should have completely resolved at least 14 days before donation AND negative 
COVID-19 PCR from nasopharyngeal swab.  
Recommendation for SARS-CoV-2 Neutralizing Antibody Titers  
Once it is confirmed that the proposed donor is no longer contagious, the next step would 
be to see if the donor has sufficient antibody levels to donate? This can be done by 
measuring SARS-CoV-2 antibody levels to ensure sufficient titers in the donor’s 
circulation. The FDA recommends a SARS-CoV-2 neutralizing antibody titer of at least 
1:160 as an inclusion criterion for donor selection. If such a matched unit is not available, 
the FDA suggests that a titer of 1:80 may be considered acceptable.  
Finding the Best Candidate for Convalescent Plasma Therapy 
Convalescent plasma therapy involves many logistical challenges, including the donor’s 
availability and willingness; apheresis center capacity; storage and transportation of 
plasma concentrate; and testing for the adequacy of antibody titers. Considering the 
aforementioned limitations and the potential risks, appropriate triage systems should be 
utilized; hence, plasma therapy use is currently restricted only to critically ill patients. 












The FDA recommends two clinical indications for the current usage of convalescent 
plasma therapy in COVID-19 patients(12) 
 Scenario A (Severe disease) which is defined as one or more of the following: 
Dyspnea, RR ≥ 30/min, blood oxygen saturation ≤ 93%, paO2 / FIO2 Ratio < 
300, and radiological worsening with the appearance of lung infiltrates > 50% 
within 24 to 48 hours.  
 Scenario B (Life-threatening disease) which is defined as one or more of the 
following: Respiratory failure, septic shock, or multi-system dysfunction.  
Another potential indication, though not proposed by the FDA, is the prophylactic use of 
convalescent plasma in vulnerable populations: [A] patients with multiple medical 
conditions, [B] health care providers, and [C] individuals with exposure to confirmed 
cases of COVID-19.  
It is unknown how long such protection might last but based on the amount and type of 
transfused antibody, immunity could last from weeks to months. Another important 
factor is the timing of plasma therapy infusion. As viremia is expected to be maximum in 
the first week, the early infusion is likely to give the best response. Possible mechanisms 
are viral neutralization and antibody-dependent cellular cytotoxicity and/or phagocytosis. 
This helps in not only clearing the viremia but also could potentially eradicate the 
reservoir of infected host cells. Currently, the only antibody source available for urgent 
use is from convalescent plasma from recovered patients. It is anticipated that as more 
people contract and recover from COVID-19, the number of potential donors will rise. 












On April 3, 2020, the FDA cleared the path for the use of this potential lifesaving therapy 
under any of the following three routes- [1] enrollment in a clinical trial, [2] via the 
national expanded access treatment protocol, and [3] under a single patient emergency 
investigational new drug application (eIND). Armed with FDA approval, researchers are 
now in the process of conducting placebo-controlled trials to test convalescent plasma, at 
numerous hospitals, including Johns Hopkins, the Mayo Clinic (NCT04325672), and 
Washington University in St. Louis (Table 1). Lacking a vaccine and with limited 
antiviral options against SARS-CoV-2, this is an ideal time to try convalescent plasma 
therapy in COVID-19 patients. 
Complications of Convalescent Plasma Therapy in Patients With COVID-19: 
Preliminary results are very encouraging, and none of the studies have thus far shown any 
significant adverse reactions. However, as experience is still limited, vigilance for 
potential side effects of convalescent plasma therapy is advised. As with any other blood 
product transfusion, there are certain common, predictable, or known side effects that 
also apply to convalescent plasma therapy, such as transfusion-related infections, serum 
sickness, fluid overload, and transfusion-related acute lung injury. By following diligent 
modern blood banking techniques and transfusion precautions, the incidence of these 
unwanted events can be minimized at any center; and the cumulative risk of any life-
threatening reactions is < 1%. Although a theoretical risk that of antibody-dependent 
enhancement of infection, this has not been witnessed to date.; and there are no data thus 
far to suggest any increased risk of convalescent plasma over ordinary fresh frozen 
plasma (13). 












Future of Convalescent Plasma Therapy 
While awaiting an effective vaccine and/or antiviral agent for COVID-19, experimental 
therapies are currently being testing in clinical trials (14). Plasma therapy has so far 
provided encouraging outcomes, without any serious events. We anticipate an upsurge in 
the use of convalescent plasma over the next several months, for the treatment of severely 
ill patients and perhaps with a role earlier in the course of illness and/or for prophylaxis. 
The American Red Cross, the U.S. government, investigators at Mayo Clinic 
(www.uscovidplasma.org), and many others across the country are now hard at work 
identifying appropriate donors and establishing testing to confirm neutralizing antibodies 
in a timely fashion. As antibody testing is validated, it should help guide the more 
effective use of convalescent plasma. In addition, efforts are underway to pursue 
production of a COVID-19 immune globulin, which might provide a more reliable, more 
effective, and more readily available plasma-based therapy against this formidable virus.  
Table 1. Recent Trials on Convalescent Plasma from United States  




NCT04342195 Acquiring Convalescent 
Specimens to Isolate and 








NCT04338360 Expanded Access to 
Convalescent Plasma for 
the Treatment of Patients 
With COVID-19 
Expanded Access Mayo Clinic (all 
centers of US) 











 NCT04340050 Pilot Study for Use of Convalescent Plasma Collected from Patients Recovered From COVID-
19 Disease for Transfusion 
as an Empiric Treatment 
During the 2020 Pandemic 










NCT04343755 Phase IIa Study Exploring 
the Safety and Efficacy of 
Convalescent Plasma from 
Recovered COVID-19 
Donors Collected by 
Plasmapheresis as 
Treatment for Hospitalized 











NCT04344015 The goal of this study is to 
identify individuals who 
have previously been 
infected with COVID-19 
and collect plasma from 
those who meet inclusion 












NCT04343261  Convalescent Plasma in the 










NCT04344535 A Randomized Trial 
Comparing the Efficacy and 
Safety of High-Titer Anti-
SARS-CoV-2 Plasma vs. 
Standard Plasma in 
Hospitalized Patients With 
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